Abiraterone derivatives, their manufacture and use
Abiraterone derivatives with structural modifications address absorption issues and side effects, enhancing efficacy and tolerance in prostate cancer treatment and acne therapy.
Patent Information
- Application Number
- JP2023579578
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-08-18
- Filing Date
- 2022-07-02
- Publication Date
- 2026-11-19
- Estimated Expiration
- 2042-07-02
AI Technical Summary
Abiraterone acetate causes significant abdominal distension and has variable absorption due to food effects, leading to inconsistent drug efficacy and gastrointestinal side effects, with metabolite M2 absent in current formulations.
Development of abiraterone derivatives with specific structural modifications, including substituted aromatic rings and heterocyclic groups, to enhance stability and absorption, resulting in higher blood concentrations of M1 and reduced gastrointestinal side effects.
The abiraterone derivatives exhibit improved tolerance, higher blood concentrations of M1, superior inhibitory effects on prostate cancer, and fewer gastrointestinal side effects compared to abiraterone acetate, while also treating acne.
Smart Images

Figure 0007954172000001 
Figure 0007954172000002 
Figure 0007954172000003
Abstract
Description
[Technical Field]
[0001] This invention belongs to the field of pharmaceuticals and, more specifically, relates to abiraterone derivatives, their manufacture, and their use. [Background technology]
[0002] The structural formula of abiraterone is as follows: [ka]
[0003] The chemical name is 17-(3-pyridyl)androsta-5,16-dien-3β-ol. It is a CYP17 inhibitor and is clinically used primarily in combination with prednisone to treat patients with metastatic, castration-refractory prostate cancer who have previously received chemotherapy including docetaxel. Abiraterone acetate (ZYTIGA) is converted in the body to abiraterone, an androgen biosynthesis inhibitor that inhibits 17α-hydroxylase / C17,20-lyase (CYP17). This 17α-hydroxylase / C17,20-lyase (CYP17) is expressed in the testes, adrenal glands, and prostate tumor tissue and is necessary for androgen biosynthesis. Abiraterone is used clinically in the form of abiraterone acetate. Because the absorption of abiraterone acetate is greatly affected by food and varies significantly between individuals, abiraterone acetate should be taken on an empty stomach. One of the metabolites of abiraterone acetate is abbreviated as M1 and has the chemical name 17-(3-pyridine)-4,16-dieneandrost-3-one (English name 17-(3-pyridine)-4,16-dieneandrost-3-one).
[0004] In a previous study, the inventors discovered that in tumor model mice inoculated with Vcap (human prostate cancer cells) and injected abiraterone acetate intraperitoneally, some model mice developed abdominal distension and death after the drug was injected intraperitoneally, and after dissection, some of the drug was not absorbed. SUMMARY OF THE INVENTION PROBLEMS TO BE SOLVED BY THE INVENTION
[0005] The present invention provides abiraterone derivatives and processes for preparing the same. Compared with abiraterone, the abiraterone derivatives according to the present invention exhibit a relatively less abdominal distension phenomenon, and have higher efficacy and tolerance. As can be seen from pharmacokinetic experiments, after intragastric administration at an equimolar dose, the blood concentration of M1 is significantly higher than that of abiraterone acetate, M2 is detected in the metabolites, while M2 is absent in the metabolites of abiraterone acetate. The abiraterone derivatives have a significantly superior inhibitory effect on prostate cancer compared to abiraterone, and have fewer gastrointestinal side effects than abiraterone. In addition, the compounds according to the present invention have an effect of treating acne. CHEMICAL FORMULA ZONK1901-1 ZONK1901-2 (M1) (M2) MEANS FOR SOLVING THE PROBLEMS
[0006] The structural formula of the abiraterone derivative according to the present invention is represented by Formula I, CHEMICAL FORMULA Formula I In Formula I, R is CHEMICAL FORMULA selected from (Ar represents a substituted or unsubstituted aromatic ring, specifically a benzene ring or a pyridine ring, and the substituent may be a C1-C8 alkyl group, a C1-C8 alkoxy group, or a halogen), Here, R1 and R2 are independently selected from H, (C3-C8) carbocycloalkyl groups, substituted or unsubstituted (C1-C18) (specifically C2-C6) alkanes (the substituents may be amino groups (amino groups do not contain active hydrogen when terminal), carboxyl groups (carboxyl groups do not contain active hydrogen when terminal), halogens, (C3-C8) heterocycloalkyl groups), (C2-C8) alkenyl groups or substituted (C2-C8) alkenyl groups, (C2-C8) alkynyl groups or substituted (C2-C8) alkynyl groups, (C6-C20) aryl groups or substituted (C6-C20) aryl groups, (C2-C20) heterocyclic groups or substituted (C2-C20) heterocyclic groups. Alternatively, R1 and R2 may form a ring with each other to become a (C3-C8) heterocycloalkyl group or a substituted (C3-C8) heterocycloalkyl group, a (C6-C20) heteroaryl group or a substituted (C6-C20) heteroaryl group. R [ka] In this case, R1 and R2 are not unsubstituted alkanes with one or more carbon atoms.
[0007] The substituents of the above compounds do not include those whose terminal substituents are hydroxyl, amino, carboxyl, phosphoryl, or sulfonyl groups, but they do include substituents in which the active hydrogen of a hydroxyl, amino, carboxyl, phosphoryl, or sulfonyl group is substituted. Experiments have shown that all compounds with active hydrogen groups at their terminals are unstable. As can be seen from the experiments, when R1 and R2 are unsubstituted amino groups, or when the terminals of R1 and R2 are unsubstituted amino groups, stable compound samples cannot be obtained, and similarly, when the terminals of R1 and R2 are carboxyl groups, stable compound samples cannot be obtained.
[0008] When the terminal amino group is substituted or forms an amide bond, the following compounds can be obtained, which have the characteristics described in the present invention. Even when the terminal is a carboxyl group, compound samples cannot be obtained due to stability issues. However, when the carboxyl group forms an ester with an alcohol or substituted alcohol, and forms an amide with an amine or substituted amine, and the terminal is not substituted with an amino group or a carboxyl group, a stable sample can be obtained, which has the characteristics described in the invention. [ka] TIFF0007954172000007.tif40170
[0009] [ka] In this case, when R2 is H and R1 is a linear alkyl group having one or more C atoms, for example, when R1 is -CH3, the drug concentrations of M1 and M2 in the body (see pharmacokinetic examples for structure) are significantly lower than those of other compounds. This is because linear alkyl groups are highly lipophilic, making them poorly absorbed and less susceptible to hydrolysis in the body.
[0010] Specifically, the typical forms of abiraterone derivatives represented by the above formula I are as follows: [ka] TIFF0007954172000010.tif218170 TIFF0007954172000011.tif244170 TIFF0007954172000012.tif227170 TIFF0007954172000013.tif219170 TIFF0007954172000014.tif231170 TIFF0007954172000015.tif212170
[0011] The abiraterone derivative represented by formula I above is produced by a method comprising the following steps, according to the reaction flowchart shown in Figure 1. [ka]
[0012] 1. Using abiraterone as a raw material, compound a is obtained by oxidation reaction in the presence of aluminum isopropoxide and cyclohexanone. 2. Under alkaline conditions, compound a and hydroxylamine hydrochloride are condensed to obtain compound b. 3. Compound b is directly esterified with the carbonyl compound of segment R to obtain an abiraterone derivative represented by formula I, or compound b is activated with carbonyl diimidazole and then condensed with the corresponding alcohol or ammonia of segment R to obtain an abiraterone derivative represented by formula I.
[0013] 1. Use in the manufacture of eukaryotic tumor cell proliferation inhibitors, 2. The use of abiraterone derivatives represented by Formula I, including their use in the manufacture of drugs for the prevention and / or treatment of tumors, falls within the scope of protection of the present invention.
[0014] The aforementioned eukaryote is a mammal, The aforementioned tumor cells are cancer cells, The aforementioned cancer cells are prostate cancer cells. The tumor is cancer, and the cancer is prostate cancer.
[0015] The aforementioned prostate cancer is metastatic, castration-refractory prostate cancer that has previously received chemotherapy including docetaxel.
[0016] The eukaryotic tumor cell proliferation inhibitor according to the present invention comprises an abiraterone derivative represented by formula I.
[0017] The use of the compound represented by formula I in the manufacture of drugs for treating acne also falls within the scope of protection of this invention.
[0018] The drug for treating acne according to the present invention comprises an abiraterone derivative represented by formula I. [Effects of the Invention]
[0019] The abiraterone derivative according to the present invention exhibits relatively less abdominal distension compared to abiraterone, possesses higher efficacy and tolerance, and, as can be seen from pharmacokinetic experiments, after intragastric administration at equimolar doses, the blood concentration of M1 is significantly higher than that of abiraterone acetate, and M2 is detected as a metabolite, whereas M2 is not present as a metabolite of abiraterone acetate. It has significantly superior inhibitory activity against prostate cancer compared to abiraterone, and has fewer gastrointestinal side effects than abiraterone. Furthermore, the compound according to the present invention has an effect in treating acne. [Modes for carrying out the invention]
[0020] The present invention will be described below with reference to specific examples, but the present invention is not limited to these.
[0021] Unless otherwise specified, the experimental methods used in the following examples are all general methods, and unless otherwise specified, the reagents, materials, etc. used in the following examples are all commercially available.
[0022] Example 1: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-((2-(dimethylamino)ethyl)carbamoyl)oxime [ka] 1.(8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one [ka] Abiraterone (35.0 g, 100 mmol, 1.0 eq), aluminum isopropoxide (20.5 g, 100 mmol, 1.0 eq), and cyclohexanone (29.5 g, 300 mmol, 3.0 eq) were weighed out and placed in a round-bottom reaction flask. Toluene (210 mL) was added, and the mixture was heated at 100°C for 16 hours under the protection of nitrogen gas to allow the reaction to proceed. The reaction mixture was cooled, saline solution was added, insoluble matter was filtered through diatomaceous earth, the organic layer was separated, and the mixture was purified by column chromatography to obtain a white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one (30.2 g, 87.0%). 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.77-7.29(m,2H),5.96(m,1H),5.85(s,1H),2.99(m,2H),2.37-1.27(m,21H).ESI-MS m / z:348.1[M+H]+.
[0023] 2. (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-oneoxime [ka] (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one (30.0 g, 86.5 mmol, 1.0 eq) was weighed and dissolved in anhydrous ethanol (250 mL). Then, hydroxylamine hydrochloride (12.0 g, 173 mmol, 2.0 eq) and sodium acetate (21.3 g, 260 mmol, 3.0 eq) were added, and the mixture was reacted at room temperature for 3 hours. Excess water was added to the reaction mixture, and a white solid precipitated. The crude product was filtered and recrystallized with ethanol to obtain (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-oneoxime (25.0 g, 80.0%). 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.77-7.29(m,2H),5.96(m,1H),5.85(s,1H),4.62(s,1H),2.99(m,2H),2.37-1.27(m,21H).ESI-MS m / z:363.1[M+H]+.
[0024] 3. (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(1H-imidazole-1-carbonyl)oxime [ka] (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-oneoxime (2.0 g, 5.52 mmol, 1.0 eq) was dissolved in dichloromethane (20 mL), and triethylamine (1.11 g, 11.0 mmol, 2.0 eq) and carbonyldiimidazole (1.78 g, 11.0 mmol, 2.0 eq) were added separately. The mixture was stirred at room temperature for 8 hours. The reaction mixture was extracted with water, and the organic phase was concentrated. Column chromatography yielded (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(1H-imidazole-1-carbonyl)oxime (2.0 g, 79.5%). 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),8.14(s,1H),7.77-7.14(m,4H),5.96(m,1H),5.85(s,1H),2.99(m,2H),2.37-1.27(m,21H).ESI-MS m / z:457.1[M+H]+.
[0025] 4. (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-((2-(dimethylamino)ethyl)carbamoyl)oxime [ka] (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(1H-imidazole-1-carbonyl)oxime (2.0 g, 4.39 mmol, 1.0 eq) was dissolved in dichloromethane (10 mL), and N,N-dimethylethylenediamine (0.58 g, 6.58 mmol, 1.5 eq) was added dropwise, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was concentrated and purified by column chromatography to obtain the solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-((2-(dimethylamino)ethyl)carbamoyl)oxime (1.5 g, 7.8%). 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.77-7.29(m,2H),5.96(m,1H),5.85(s,1H),3.28-3.26(d,4H),2.36(s,6H),2.37-1.27(m,23H).ESI-MS m / z:477.1[M+H]+.
[0026] Example 2: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl))-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-dimethylcarbamoyl oxime [ka] (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-oneoxime (2.0 g, 5.52 mmol, 1.0 eq) and triethylamine (1.11 g, 11.0 mmol, 2.0 eq) were each dissolved in dichloromethane (20 mL), and dimethylcarbamoyl chloride (1.19 g, 11.0 mmol, 2.0 eq) was added dropwise, and the mixture was reacted at room temperature for 5 hours. The reaction mixture was concentrated, and column chromatography yielded a white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-dimethylcarbamoyl oxime (2.0 g, 83.7%). 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.77-7.29(m,2H),5.96(m,1H),5.85(s,1H),3.47(s,6H),2.37-1.27(m,23H).ESI-MS m / z:434.1[M+H]+.
[0027] Example 3: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(bis(2-chloroethyl)carbamoyl)oxime [ka] The synthesis methods of Examples 1 and 2 were combined to obtain bis(2-chloroethyl)carbamoyl chloride and the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one oxime, which is a white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(bis(2-chloroethyl)carbamoyl)oxime. 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.77-7.29(m,2H),5.96(m,1H),5.62(s,1H),3.64(m,4H),3.24(m,4H),2.37-1.27(m,23H).ESI-MS m / z:532.1[M+H]+.
[0028] Example 4: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-([1,4'-bipiperidine]-1'-carbonyl)oxime [ka] The synthesis methods of Examples 1 and 2 are summarized as follows: [1,4'-bipiperidine]-1'-carbonyl chloride and the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-oneoxy The esterification of the oxime yielded the white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-([1,4'-bipiperidine]-1'-carbonyl)oxime. 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.77-7.29(m,2H),5.96(m,1H),5.62(s,1H),3.39(m,4H),2.62-2.42(m,5H),2.37-1.27(m,33H).ESI-MS m / z:557.1[M+H]+.
[0029] Example 5: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(2-methylbenzoyl)oxime [ka] The synthesis methods of Examples 1 to 2 are summarized as follows: o-toluoyl chloride is esterified with the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one oxime to obtain (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one O-(2-methylbenzoyl)oxime as a white solid. 1 1H NMR (DMSO-d6, 400 MHz) δ 8.47 (s, 1H), 8.33 (d, 1H), 7.88-7.29 (m, 6H), 5.96 (m, 1H), 5.62 (s, 1H), 2.37-1.27 (m, 26H). ESI-MS m / z: 481.1 [M+H]+.
[0030] Example 6: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one O-(3-(methylamino)propionyl)oxime [Chemical Formula] The synthesis methods of Examples 1 to 2 are summarized as follows: 3-methylaminopropionic acid is esterified with the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one oxime, followed by deprotection, to obtain (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one O-(3-(methylamino)propionyl)oxime as a white solid. 1H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.77-7.29(m,2H),5.96(m,1H),5.62(s,1H),3.62(s,3H),2.83-2.63(m,4H),2.37-1.27(m,23H).ESI-MS m / z:448.1[M+H]+.
[0031] Example 7: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-acetyloxime [ka] The synthesis methods of Examples 1 and 2 were combined to obtain the white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one oxime. After esterification, the mixture was deprotected to obtain the white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-acetyloxime. 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.77-7.29(m,2H),5.96(m,1H),5.62(s,1H),2.37-1.27(m,26H).ESI-MS m / z:405.1[M+H]+.
[0032] Example 8 Synthesis of ((((((8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-7,8,9,11,12,13,14,15-octahydro-1H-cyclopenta[a]phenanthrene-3(2H,6H,10H)-ylidene)amino)oxy)carbonyl)oxy)methylisobutyrate [ka] The synthesis methods of Examples 1 and 2 were combined to obtain chloromethyl chloroformate and the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-oneoxime, followed by esterification with isobutyric acid to obtain the white solid ((((((8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-7,8,9,11,12,13,14,15-octahydro-1H-cyclopenta[a]phenanthrene-3(2H,6H,10H)-ylidene)amino)oxy)carbonyl)oxy)methyl isobutyrate. 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.70-7.29(m,2H),6.95(s,1H),5.96(m,1H),5.62(s,1H),2.67-1.14(m,30H).ESI-MS m / z:507.1[M+H]+.
[0033] Example 9: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-((2-morpholinoethoxycarbonyl)oxime) [ka] Combining the synthesis methods of Examples 1 and 2, 2-morpholinoethanol and the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one oxime were used to form the carbonate ester (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-((2-morpholinoethoxycarbonyl)oxime) under a triphosgene environment. 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.70-7.29(m,2H),5.96(m,1H),5.62(s,1H),4 .43(m,2H),3.65(m,4H),2.97(m,2H),2.36(m,4H),2.12-1.12(m,23H).ESI-MS m / z:520.1[M+H]+.
[0034] Example 10: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-piperidine-4-carbonyloxime [ka] The synthesis methods of Examples 1 and 2 were combined to obtain the white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one oxime by esterifying the intermediate. 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.70-7.29(m,2H),5.96(m,1H),5.62(s,1H),2.79(m,4H),2.33-1.27(m,28H).ESI-MS m / z:474.1[M+H]+.
[0035] Example 11: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(1-methylpiperidine-4-carbonyl)oxime [ka] The synthesis methods of Examples 1 and 2 were combined to obtain the white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one oxime by esterifying it with the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(1-methylpiperidine-4-carbonyl)oxime.1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.70-7.29(m,2H),5.96(m,1H),5.62(s,1H),2.79(m,4H),2.33-1.27(m,31H).ESI-MS m / z:488.1[M+H]+.
[0036] Example 12: Synthesis of 1-(4-(((((8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-7,8,9,11,12,13,14,15-octahydro-1H-cyclopenta[a]phenanthrene-3(2H,6H,10H)-ylidene)amino)oxy)carbonyl)piperidine-1-yl)ethanone [ka] The synthesis methods of Examples 1 and 2 are summarized as follows: 1-acetylpiperidine-4-carboxylic acid is esterified with the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-oneoxime. This yielded a white solid 1-(4-(((((8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-7,8,9,11,12,13,14,15-octahydro-1H-cyclopenta[a]phenanthrene-3(2H,6H,10H)-ylidene)amino)oxy)carbonyl)piperidine-1-yl)ethanone. 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.70-7.29(m,2H),5.96(m,1H),5.62(s,1H),3.39(m,4H),2.33-1.27(m,31H).ESI-MS m / z:516.1[M+H]+.
[0037] Example 13: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(1-(2-(dimethylamino)ethyl)piperidine-4-carbonyl)oxime [ka] The synthesis methods of Examples 1 and 2 were combined to produce 1-(2-(dimethylamino)ethyl)piperidine-4-carboxylic acid and the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-oneoxime The two were esterified to obtain the white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(1-(2-(dimethylamino)ethyl)piperidine-4-carbonyl)oxime. 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.70-7.29(m,2H),5.96(m,1H),5.62(s,1H),2.66(m,6H),2.41-2.37(m,8H),2.36-1.27(m,28H).ESI-MS m / z:545.1[M+H]+.
[0038] Example 14: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(1-(cyclopropanesulfonyl)piperidine-4-carbonyl)oxime [ka] The synthesis methods of Examples 1 and 2 were combined to obtain the white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one oxime by esterifying it with the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(1-(cyclopropanesulfonyl)piperidine-4-carbonyl)oxime. 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.70-7.29(m,2H),5.96(m,1H),5.62(s,1H),2.91(m,4H),2.36-1.27(m,33H).ESI-MS m / z:578.1[M+H]+.
[0039] Example 15: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(1-(cyclopropanemethyl)piperidine-4-carbonyl)oxime [ka] The synthesis methods of Examples 1 and 2 were combined to obtain the white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one oxime by esterifying it with the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-(1-(cyclopropanemethyl)piperidine-4-carbonyl)oxime. 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.70-7.29(m,2H),5.96(m,1H),5.62(s,1H),2.41(m,4H),2.36-1.27(m,35H).ESI-MS m / z:528.1[M+H]+.
[0040] Example 16: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-((S)-1-methylpyrrolidine-2-carbonyl)oxime [ka] The synthesis methods of Examples 1 and 2 were combined to obtain (S)-1-methylpyrrolidine-2-carboxylic acid and the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one oxime, which is a white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-((S)-1-methylpyrrolidine-2-carbonyl)oxime. 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.70-7.29(m,2H),5.96(m,1H),5.62(s,1H),3.08(m,1H),2.36-1.27(m,32H).ESI-MS m / z:474.1[M+H]+.
[0041] Example 17: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-tetrahydro-2H-pyran-4-carbonyloxime [ka] The synthesis methods of Examples 1 and 2 were combined to obtain the white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one oxime by esterifying the intermediate. 1 H NMR(DMSO-d6 400 MHz)δ8.47(s,1H),8.33(d,1H),7.70-7.29(m,2H),5.96(m,1H),5.62(s,1H),3.55(m,4H),2.36-1.27(m,28H).ESI-MS m / z:475.1[M+H]+.
[0042] Example 18: Synthesis of (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-nicotin oxime [ka] The synthesis methods of Examples 1 and 2 were combined to obtain the white solid (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one oxime by esterifying nicotinic acid with the intermediate (8S,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridine-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthrene-3(2H)-one O-nicotinic acid oxime. 1H NMR(DMSO-d6 400 MHz)δ8.88(s,1H),8.65(d,1H),8.47(s,1H),8.33(d,1H),7.70-7.29(m,4H),5.96(m,1H),5.62(s,1H),2.36-1.27(m,23H).ESI-MS m / z:468.1[M+H]+.
[0043] Example 19: Pharmacodynamic experiment on prostate tumor The inhibitory effects of compounds from the ZONK1901 series (the compound of the invention) and ZONK1901-10 (abiraterone acetate) on in vivo tumor growth in nude mouse transplant tumor models inoculated with human prostate cancer cell VCaP were tested.
[0044] Test samples: Compound (B) from Example 1, Compound (C) from Example 2, Compound (D) from Example 3, (E) from Example 4, (F) from Example 5, (G) from Example 6, (H) from Example 7, and ZONK1901-19, ZONK1901-10(I) (abiraterone acetate) [ka] ZONK1901-19 (Group J)
[0045] reagent: DMEM culture medium, fetal bovine serum, trypsin, penicillin / streptomycin solution, dimethyl sulfoxide (DMSO), TPGS, Matrigel, PBS (pH 7.4, 0.01M) 90 male BALB / c nude mice (6-7 weeks old) were purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd. and reared in the SPF animal room of Suzhou Shengsu New Drug Development Co., Ltd. The temperature was maintained at 20-25°C and the relative humidity at 40-70%, with 12 hours of illumination under both bright-field and dark-field lighting. The animals were allowed to drink water and feed freely. After approximately 6 days of normal rearing, mice in good health were selected for this experiment based on veterinary examination. Before dividing the animals into groups, marks were made on the tail ridges using a marker pen. After dividing the animals into groups, each animal was marked with a notch in its ear.
[0046] Human prostate cancer cell line VCaP was purchased from the Shanghai Cell Library of the Chinese Academy of Sciences (CAS, which is cryopreserved in liquid nitrogen in this laboratory).
[0047] VCaP cells were cultured under normal conditions in DMEM medium containing 10% fetal bovine serum at 5% CO2 and 37°C. The cells were digested with 0.25% trypsin and subcultured 2-3 times per week depending on the cell proliferation status, with a subculture ratio of 1:3 to 1:5.
[0048] VCaP cells in the logarithmic growth phase were collected, counted, and then resuspended in 50% DMEM basic medium and 50% Matrigel Matrix to achieve a cell concentration of 5 × 10⁶. 7 Prepare the cell suspension to the required concentration (1 × 10⁶ cells / mL), place the cells in an icebox, draw the cell suspension with a 1 mL syringe, and inject it subcutaneously into the anterior right axilla of nude mice. Each animal receives 200 μL (1 × 10⁶). 7 VCaP-transplanted tumor models were constructed by inoculating the animals with cells (per animal). The animals' condition was observed regularly, tumor diameter was measured using electronic calipers, and the data was entered into an Excel spreadsheet to calculate tumor volume and monitor tumor growth. Tumor volume was 100-300 mm². 3 When the target was reached, 60 animals in good health with similar tumor volumes were selected and divided into 10 groups (n=6) using the randomized block method based on tumor volume, while ensuring as much as possible that the average body weight of each group was the same. The day the groups were divided was designated as Day 1 of the experiment (D1). After the start of the experiment, the tumor diameter was measured twice a week, the tumor volume was calculated, and the body weight of the animals was weighed and recorded.
[0049] The formula for calculating tumor volume (TV) is as follows: TV (mm 3 ) = l × w 2 / 2 In the formula, l represents the longest diameter (mm) of the tumor, and w represents the shortest diameter (mm) of the tumor.
[0050] Preparation of DMSO, PEG400, and PG (v:v:v, 10:60:30): Appropriate amounts of DMSO, PEG400, and PG were drawn up and mixed uniformly. The ratio of DMSO, PEG400, and PG in the mixture was set to 10:60:30 (v:v:v), and the mixture was stored at room temperature as a blank solvent.
[0051] Preparation of the administered formulation: An appropriate amount of the test compound was placed in a glass bottle, an appropriate amount of the solvent DMSO was added, and vortex ultrasound was performed. Then, appropriate amounts of PEG400 and PG were added in sequence and mixed uniformly by vortex to obtain a dosage formulation with a final concentration of 0.05 M. After individual packaging, the formulations were stored in a refrigerator at 2-8°C, and uniform mixing was performed by vortex vibration before each administration. Preparations were made every 7 days, individually packaged, and stored in a refrigerator at 4°C.
[0052] Preparation of ZONK1901-10 dosage formulation: Place an appropriate amount of ZONK1901-10 in a glass bottle, add an appropriate amount of corn oil, and vortex to thoroughly mix until the final concentration is 19.58 mg / mL. -1 A (0.05M) dosage formulation was obtained. After individual packaging, it was stored in a refrigerator at 2-8°C, and before each administration, it was vibrated with a vortex mixer to ensure uniform mixing. A new preparation was made every 7 days, individually packaged, and stored in a refrigerator at 4°C.
[0053] Refer to Table 1 for animal grouping and administration plan. The test samples will be administered from the day of grouping, and after 28 days, or when the tumor volume of the solvent control group reaches 2000 mm³. 3 The experiment will be terminated when the target is reached (the first to reach the target is used as the criterion), and the administered volume will be 10 mL·kg in all cases. -1 The following was done. Group A was the blank solvent group, and the blank solvent (DMSO&PEG400&PG(v:v:v, 10:60:30)) was administered intragastricly once daily (QD). The other groups were all administered intragastricly once daily (QD). For Group I, ZONK1901-10 was administered intragastricly once daily (QD), with a dose of 195.8 mg·kg. -1 (0.5 mmol·kg) -1 ) TIFF0007954172000040.tif142170
[0054] On the final day of the experiment, the animals were weighed, the tumor diameter was measured, and then euthanized (CO2). The tumor tissue was removed, weighed, photographed, and the tumor inhibition rate was calculated. Gross dissection was performed on the animals to visually check for any organ abnormalities. The animal carcasses and tumor tissue were disposed of together in a carcass storage refrigerator.
[0055] Data recording, calculation formulas: The formula for calculating relative tumor volume (RTV) is as follows: RTV=TV t / TV initial
[0056] During the ceremony, TV initial This is the tumor volume measured when administered to each group, and TV t This is the tumor volume measured each time during the administration period.
[0057] The formula for calculating the relative tumor growth rate (%T / C) is as follows: %T / C=100%×(RTV T / RTV C )
[0058] During the ceremony, RTV T This represents the RTV of the treatment group, and RTV C This represents the RTV of the solvent control group.
[0059] The formula for calculating the tumor growth inhibition rate (TGI) (%) is as follows: TGI = 100% × [1 - (TV t(T) -TV initial(T) ) / (TV t(C) -TV initial(C) )]
[0060] During the ceremony, TV t(T) This represents the tumor volume of the treatment group measured each time, TV initial(T) This represents the tumor volume of the treatment group when administered to each group, and TV t(C)This represents the tumor volume of the solvent control group measured each time, and TV initial(C) This represents the tumor volume of the solvent control group when administered to each group.
[0061] The formula for calculating the percentage of weight loss in animals is as follows: Animal weight loss rate = 100% × (BW initial -BW t ) / BW initial
[0062] During the ceremony, BW t This represents the body weight of the animal measured each time during the administration period, BW initial This represents the body weight of the animals when administered to each group.
[0063] The formula for calculating the tumor inhibition rate (IR) is as follows: IR = 100% × (W C -W T ) / W C
[0064] In the formula, W C This represents the tumor weight of the control group, W T This represents the tumor weight in the treatment group. TIFF0007954172000041.tif98170
[0065] Note: "*" indicates a significant difference in tumor volume compared to the solvent control group (P<0.05), and "**" indicates a very significant difference in tumor volume compared to the solvent control group (P<0.01).
[0066] Example 20: Pharmacokinetic experiment [ka] ZONK1901-19 (Group H) We studied the pharmacokinetic properties of the drug after intragastric administration in mice.
[0067] 45 male mice were randomly divided into 9 groups (each containing 5 mice) and administered compound (B) from Example 1, compound (C) from Example 2, compound (D) from Example 3, compound (E) from Example 4, compound (F) from Example 5, compound (G) from Example 6, and ZONK1901-19(H) and ZONK1901-10(I) (abiraterone acetate).
[0068] Data was collected for each mouse at two to three discontinuous time points.
[0069] We established an LC-MS / MS analysis method to measure the concentrations of ZONK1901-1 and ZONK1901-2 in mouse whole blood. Using the obtained blood concentration data, we calculated the relevant pharmacokinetic parameters using the Pharsight Phoenix WinNonlin8.0 non-compartment model pharmacokinetic processing software. [ka] ZONK1901-1 ZONK1901-2 (M1) (M2)
[0070] The main pharmacokinetic parameters of ZONK1901-1 and ZONK1901-2, metabolites of each group after intragastric administration, are shown in the table below. TIFF0007954172000044.tif138170
[0071] Example 21: Acne pharmacodynamic test 140 healthy Japanese white rabbits, weighing 2.0-2.5 kg, were used, all male. After 1 week of adaptive rearing, 10 rabbits were randomly selected as a normal control group based on their weight, and the remaining 130 rabbits were subjected to a 2x2 cm injection at a location 2 cm outside the ear canal. 2Within the specified range, coal tar was applied once a day to a thickness of approximately 0.5 mm. (Before application, the coal tar was heated and melted in a water bath, and each time coal tar was applied, the previously applied coal tar layer was removed, and olive oil was applied to the normal control group, using the same method as before.) Three weeks after constructing the model, 130 rabbits were randomly divided into 13 groups according to the degree of skin damage, namely the model control group, compound from Example 1 (Group 1), compound from Example 2 (Group 2), compound from Example 3 (Group 3), Example 4 (Group 4), Example 5 (Group 5), Example 6 (Group 6), Example 7 (Group 7), Example 8 (Group 8), Example 9 (Group 9), Example 10 (Group 10), Example 11 (Group 11), Example 12 (Group 12), and Example 13 (Group 13), with 10 rabbits in each group. After dividing the animals into groups, coal tar was applied to each dose group daily in the morning, and after removing the coal tar in the afternoon, the test drug or control drug was applied once a day to the injured area (both 0.01% / 10g paste, 1g paste per animal), and this was continued for two consecutive weeks (equal amounts of substrate were applied to the model control group and the normal control group). 24 hours after the last administration, the animals were killed by air embolization, and skin (full thickness) from the administration site in the ear was taken, fixed with 4% paraformaldehyde solution, stained with HE, and subjected to standard pathological observation.
[0072] 1. Experimental Results TIFF0007954172000045.tif123170
[0073] An asterisk (*) indicates that P < 0.05 compared to the control group, and a double asterisk (**) indicates that P < 0.01 compared to the control group.
[0074] As can be seen from Table 4 above, compared to the model control group, the amount of keratinized tissue in the hair follicles of the rabbits' ears in each group is improved. TIFF0007954172000046.tif123170
[0075] "**" indicates that P < 0.01 compared to the model control group, and "*" indicates that P < 0.05 compared to the model control group.
[0076] As can be seen from Table 5 above, the degree of inflammatory cell infiltration in the ears of rabbits in each group is improved compared to the model control group.
Claims
1. An abiraterone derivative which is one of the following:
2. Use of the abiraterone derivative according to Claim 1 in the following: 1) Use in the manufacture of growth inhibitors for mammalian prostate cancer cells; or 2) Use in the manufacture of drugs for the prevention and / or treatment of prostate cancer.
3. The use according to claim 2, wherein the prostate cancer is metastatic castration-refractory prostate cancer that has previously received chemotherapy including docetaxel.
4. A drug for preventing and / or treating prostate cancer, comprising the abiraterone derivative described in claim 1.
5. Use of the abiraterone derivative according to claim 1 in the manufacture of a drug for treating acne.
6. A drug for treating acne, comprising the abiraterone derivative described in claim 1.
Citation Information
Patent Citations
Steroid 5Alpha-reductase inhibitors, preparation methods thereof and medical applications thereof
CN102532236A
Compound serving as inhibitor for CYP11B, CYP17 and CYP21
CN106279343A
Compound for treating prostatic cancers, preparation method therefor and use of compound
CN107226834A
